evaluate the long-term efficacy and safety of leflunomide (LEF) as induction treatment in a series of TA patients based on the Chinese cohort. Methods: Fifty-six patients from the East China TA cohort treated with LEF at least 3 months were enrolled in this study, including the naïve LEF treatment patients (n ¼ 41) and the cyclophosphamide-(CYC-) resistant LEF treatment patients (n ¼ 15). Data in clinical features, Kerr score and angiography were collected. Response to treatment was categorized as clinical remission (CR) and clinical improvement (CI) after 6 and 12 months of treatment. Results: The total rates of CR and CI were 67.86% and 16.07% after 6 months, and 55.36% and 14.29% after 12 months, respectively. ESR and CRP levels and Kerr scores decreased significantly after 12 months of LEF treatment (P < 0.05). Patients of CYC-resistant switched to LEF and reached the CR and CI rates of 60.00% (9/15) and 26.67% (4/15) after 6 months, and 73.33% (11/15) and 6.67% (1/15) after 12 months, respectively, with decrease in Kerr scores (all P < 0.05). After following up of 14.44 AE 6.86 months, 48 patients (85.71%) possessed LEF treatment with good tolerance. One patient died of the progression of TA after 2 months, 2 patients relapsed, and 3 patients with side effects were switched to other immunosuppressive agents. Conclusions: LEF led to quick induction and sustained remission of TA, especially in refractory cases, and therefore, should be an alternative long-term treatment for TA.
Background: ANCA-associated vasculitis (AAV) is a severe systemic disease and acute and long term damage from underlying disease and therapy are a problem. The demographics of AAV imply that patients will have comorbidity which will impact treatment decisions and clinical outcomes. Infection is an important problem early in therapy and there are concerns over treatment related adverse events (AEs) in particular because of the use of high doses of glucocorticoids over a long period of time. This study examined real world practice of AAV treatment in Europe to understand comorbidity and the impact of induction treatment over the first 12 months in terms of AEs and infections. Methods: A retrospective study was performed on 1197 patients (929 incident and 268 relapsing patients) receiving care from 399 physicians in 4 European countries. Patients were referred between 2014-17 and data was collected retrospectively at baseline and 1, 3, 6 and 12 months following commencement of induction therapy. Results: Comorbidity at initiation of induction treatment was very common in both incident and in particular relapsing patients. Only 32.2% of incident and 16% of relapsing patients were free from comorbidity. Commonly observed comorbidities were hypertension (incident 44.9%, relapsing 52.6%), diabetes (19.3%, 24.6%), COPD/asthma (15.5%, 19.4%), coronary arterial disease (10.0%, 16.0%). Osteoporosis (7.3%, 13.8%), and body mass index > 35 (6.4%, 11.9%). In the 12 months following commencement of induction treatment AEs were commonly observed in both groups and many patients had 1 or more infections in particular upper (URTI) and lower (LRTI) respiratory tract infections and urinary tract infections (UTI) as shown in table (% of patients experiencing event). Both AEs and infections were more common in the first 3 months of treatment when glucocorticoid dose is highest. Conclusion: Incident and in particular relapsing patients frequently have important comorbidity at the time of induction therapy. This is particularly relevant when considering that treatment related AEs and infections are so common especially in the first 3 months of treatment. Consideration to the impact of comorbidity and induction therapy risks are important when making treatment decisions in AAV. Disclosures: Authors are employees of Vifor Pharma. This work was funded by Vifor Pharma.
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there is little published evidence. This study aimed examined the scope and content of social media conversations in order to understand challenges, unmet needs and patient experience. Methods: The study collected data using the Radarly platform and specific AAV search terms from online forums, social media channels, websites, media pages and blogs. Data was collected from 1/10/2016 until 30/9/2018 in local language from France, Germany, Portugal, Spain and UK. Qualitative analysis was performed of 257 specific comments.
Results: There were geographical differences in volume of posts mentioning AAV (1952 in UK vs under 320 in other countries) and estimated reach to users exposed to the post (1,570,000 in UK vs under 255,000 in other countries). Patient led conversations contributed most to the high UK volume whereas it was healthcare professional (HCP) and other contributor dominated elsewhere. There were differences in the use of various social media platforms. In UK Instagram is a key platform for patients sharing experience of their daily lives and awareness of AAV. Online forums were important for patient discussions in Germany and France but in Spain online patient discussion was rare. Detailed analysis of individual posts examined conversations with a framework including challenges/unmet needs, symptoms/side effects and treatments, presented in table (% of each   ii154 TREATMENT/MANAGEMENT Downloaded from https://academic.oup.com/rheumatology/article-abstract/58/Supplement_2/kez063.067/5422085 by guest on 09 July 2019
